Next-generation fusion company SHINE Technologies and WARF Therapeutics, a drug discovery programme from the Wisconsin Alumni Research Foundation (WARF), announced on Thursday promising pre-clinical research results from collaborative efforts with the Advanced Radiotheranostics Lab at the University of Wisconsin-Madison.
The studies showed that WT-7695 and ART-101, treatments that uses Ilumira, SHINE's non-carrier added lutetium-177 (Lu-177) chloride, have the potential to increase life span and be more effective in treating kidney and prostate cancer, respectively.
Partnering with UW-Madison and Morgridge Institute for Research Principal Investigators, WARF Therapeutics creates a translational research path that draws on research and an industry-focused approach to improve value propositions of drug candidates.
WARF Therapeutics has invested to accelerate the development of theranostic radiopharmaceutical programs at UW-Madison, like WT-7695 and ART-101, while SHINE Technologies provides the lutetium-177 integral to this innovative cancer treatment approach.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient